Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439

NCT02089659 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT02089659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02089659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Completed
Start date
March 26, 2014
Completion date
May 12, 2014
Enrollment
16 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection